Through daily gavage (at 6mg/kg/day) the schedules tested were devoid of toxicity and caused anti-tumor effects; however, a suppressive effect on CEPs was not detected.
Introduction
The original reports of low-dose metronomic chemotherapy (1, 2) highlighted the antiangiogenic basis for the anti-tumor effects of administering a chemotherapy drug in this fashion -at very close regular intervals (e.g. daily) using relatively low (i.e., minimally toxic) doses and with no prolonged interruptions (3) . Integration with an antiangiogenic agent such as TNP-470 or anti-VEGFR-2 monoclonal antibodies with metronomic chemotherapy can cause enhanced anti-tumor effects, which are sometimes remarkable (1, 2) and accompanied by minimal overt toxic side effects in preclinical models (2, 4) . As a result of these potential benefits a number of phase II clinical trials have been initiated; the results of a number of these trials have shown very encouraging results(5), e.g. daily low dose cyclophosphamide and bevacizumab (the anti-VEGF monoclonal antibody) for the treatment of recurrent, refractory ovarian cancer (6) , daily low-dose oral cyclophosphamide and letrozole, an aromatase inhibitor, for the treatment of metastatic breast cancer in elderly women (7) , daily low dose oral cyclophosphamide with daily low-dose capecitabine, a 5-FU prodrug, in combination with bevacizumab for the treatment of metastatic breast cancer (8) , and daily metronomic capecitabine with weekly gemcitabine and daily sorafenib in renal cell carcinoma (9) . At least four randomized phase III trials of various metronomic chemotherapy regimens are currently in progress (www.clinicaltrials.gov).
With respect to the antiangiogenic basis of administering chemotherapy in a lowdose frequent manner, a number of studies have shown that some of the endothelial cells of the tumor's expanding neovasculature undergo apoptosis as a result of exposure to metronomic chemotherapy (1, 2) which presumably leads to the reduction in microvessel density as reported in some studies (1, 10) . In addition, proangiogenic/vasculogenic bone marrow-derived cells (CEPs) can be targeted by various metronomic chemotherapy regimens (11) (12) (13) (14) . Indeed this property -reduction in CEPs -has been exploited as a surrogate pharmacodynamic biomarker in mice to determine the optimal biologic/therapeutic dose of many different drugs for metronomic chemotherapy studies including vinblastine, vinorelbine, cisplatin, cyclophosphamide and paclitaxel (15) , a nanoparticle formulation of paclitaxel (13) and UFT (tegafur plus uracil), a 5-FU prodrug (14) . However there are indications that metronomic chemotherapy may involve additional or even alternative mechanisms (3, 5) . For example low-dose cyclophosphamide has been known to stimulate the immune system, primarily by targeting the regulatory (T reg) cells thus augmenting the activity of cytotoxic T lymphocytes (CTLs) as well as other types of killer cells e.g. lymphokine-activated killer (LAK) cells (16) . This may explain the ability of metronomic cyclophosphamide to enhance the activity of anti-tumor vaccines (17) . Direct tumor cell effects caused by metronomic chemotherapy may also be a contributing factor in some cases. For example, we previously reported that the daily administration of a doublet combination of two different chemotherapy drugs-cyclophosphamide and UFT -caused exceptional long term survival of mice with established advanced (high volume) visceral metastatic disease -where therapy was initiated one month after resection of primary orthotopic human breast cancer xenografts (14) . It is unusual for drugs which only have antiangiogenic effects to bring about such a potent therapeutic effect, suggesting the possibility of a direct anti-tumor cell effect. Direct targeting of relatively small numbers of cancer stem cells could conceivably cause such an effect, for which there is some preliminary evidence (18) . Finally, there are reports that certain chemotherapy drugs administered in vivo to tumor-bearing mice can target expression of tumor associated hypoxia-inducible factor-1 (HIF-1α) -a major driver of angiogenesis (19, 20) but also many other tumor cell properties involved in growth and progression (21) Given the obvious advantage, or even necessity for using oral chemotherapy drugs in clinical or even preclinical metronomic chemotherapy experiments, we have placed considerable emphasis on the study of such agents, e.g. cyclophosphamide, UFT (14, 22) , or oral topotecan (23) , and evaluating them either as monotherapies (e.g. cyclophosphamide(11)) or as doublet treatment combinations e.g. cyclophosphamide plus UFT (14) , or in combination with targeted biologic antiangiogenic agents (23) .
The purpose of the present study was to evaluate the properties of an orally bioavailable prodrug of gemcitabine LY2334737 (Eli Lilly, Indianapolis) from a metronomic chemotherapy perspective. LY2334737 is a gemcitabine analog with an amide linked valproate (24) . The prodrug is orally absorbed intact and slowly releases gemcitabine systemically over an extended time period, consistent with formation-ratelimited kinetics. We found that this drug can be safely administered at repetitive low doses for prolonged periods with no long drug-free breaks and cause anti-tumor effects.
The anti-tumor effects were observed in two xenograft models; the LM2-4 triple negative human breast cancer model (14) , and the SKOV3-13 human ovarian carcinoma(23).
However, unlike the chemotherapy drugs we have previously studied, it did not cause systemic suppression of CEPs, nor a drop in tumor microvessel density, suggesting involvement of mechanisms largely independent of angiogenesis/vasculogenesis inhibition. As such this drug might be particularly suitable for combination with other 6 chemotherapeutic drugs which are known to induce antiangiogenic effects, including inhibition of CEPs, as the combination of two such agents may have non-overlapping, complimentary mechanisms of action. 
Materials and Methods
Drug Preparation. Gemcitabine hydrochloride was purchased from the pharmacy at the Sunnybrook Health Sciences Centre and made up in sterile saline immediately prior to i.p. administration. LY2334737 (LY, 2'-deoxy-2',2'-difluoro-N-(1-oxo-2-propylpentyl)-cytidine, hemi p-toluenesulfonic acid hemihydrate, Eli Lilly, Indianapolis) was made up (2.0mg/ml) of which 54% is gemcitabine. It was prepared and diluted as necessary in sodium phosphate (0.1M, pH6.0) every week, and stored in the dark at 4 degrees until administered by gavage.
Metronomic dosing of the LY prodrug, and of Cyclophosphamide. Female Balb/cJ mice were purchased at 6-8 weeks of age from Jackson laboratories and allowed to acclimatize for 2 weeks before used in experiments. Mice were divided into 8 groups (4 mice/group) and treated with different doses of LY p.o daily, diluent control p.o. daily, or gemcitabine HCl administered i.p every 3 days. On day 28 mice were bled and white blood count and viable CEP analysis was carried out as previously described by us (15) , and that we previously used to identify the optimal metronomic dose of different chemotherapeutic agents (12) (13) (14) . CEP analysis was calculated as the percentage of CEPs relative to the total white blood count. Cyclophosphamide was administered as an i.p. bolus (100mg/kg) on day 1 followed by continuous 20mg/kg/day dosing in the drinking water as previously described (22, 25) .
Statistical Analysis. Data are presented as mean ± standard deviation (SD). Statistical significance of differences was assessed by one way ANOVA, followed by Newman- Cell lines. We previously described the cell lines used in this study, namely the human LM2-4 breast cancer cell line (14) and the human SKOV3-13 ovarian cancer cell line (23) .
Orthotopic tumor models, intratumoral blood flow analysis, and Luciferase imaging
LM2-4 cells were co-transfected using the pGL3-luciferase (Promega) and pSVII neo vectors and selected in G418. One high luciferase expressing clone, termed LM2-4luc+, was subsequently implanted in the inguinal mammary fat pad of 6-8 week old female SCID mice (2x10 6 cells in 50 microlitre volume) as previously described (14, 26, 27) .
Tumor blood flow analysis was performed by high-frequency micro-ultrasound functional imaging as essentially described previously in the study by Franco et al (28) .
The SKOV3-13 ovarian model was previously described in Hashimoto et al (23) .
Mice were administered luciferin (a 15 mg/ml stock was made up in PBS, and administered i.p. to mice at 150 mg/kg) and were imaged 10-12 minutes later by first anaesthetizing and then imaging, described in Hashimoto et al (23) , in a IVIS200 Xenogen.
Tumor microvessel density
Microvessel density was evaluated as described elsewhere (28, 29) . Briefly, tumors were removed and cut into pieces, and then one piece per tumor was immediately frozen on 
Angiogenesis and Tumor Health Panel Analysis
Analysis was carried out on paraffin embedded LM2-4 tumor sections. Tumor blocks were sectioned as 3 μM slices onto standard microscope slides. Slides were deparaffinized, rehydrated, and antigen retrieval was performed followed by blocking 
RESULTS
Toxicity analysis and impact on CEP levels of metronomic LY. To determine the optimal biologic dose (OBD) of LY given metronomically, we administered the prodrug of gemcitabine daily by gavage to female Balb/c mice for 28 days. Doses used were 2mg/kg, 4mg/kg and 6mg/kg (Fig 1a) . For comparative purposes mice were also administered gemcitabine i.p., given every three days at doses of 40, 70 120 or 160mg/kg for a total of 9 cycles of dosing. On day 28 mice were bled and CEP analysis was carried out (Fig 1b) . We found no significant impact on host weight (as an indicator of toxicity) in any of the LY treatment groups throughout the course of the experiment. We similarly did not observe any impact of gemcitabine i.p. on mouse weights (Fig. 1a) . Surprisingly, daily dosing of LY also had no significant impact on CEP numbers as shown in Fig. 1b .
Furthermore, white blood cell counts (WBC) confirmed the relative absence of host toxicity in this experiment (Fig 1b) . Taken together, these results suggested that LY could be the first example of a chemotherapy drug which when given metronomically is not only minimally or non-toxic, but also has little or no impact on systemic angiogenesis (i.e. as measured by CEPs). It is also important to note that we used CEPs as a surrogate marker (12) for evaluating the optimal metronomic dose of LY (although out test proved inconclusive); a more accurate evaluation of the precise impact of metronomic LY on CEPs may require additional studies, with a larger number of mice per group. Impact on CEP levels and toxicity analysis of escalating doses of daily LY administration. We assessed increasing concentrations of daily doses of LY over a 7-day treatment period, with doses up to 20mg/kg/day. We found that even within this brief time frame, the higher doses (>10mg/kg) were sufficient to induce toxicity as evidenced by the severe weight loss (see Fig 2a) . However, whereas for doses of 15mg/kg and 20mg/kg the CEP analysis was complicated by the evident high host toxicity, we again did not observe an impact on CEP levels when daily non-toxic doses (<10mg/kg) of LY were administered (Fig 2b) . Taken together, these results suggest that daily LY doses that do not cause overt toxicity (i.e. 6-8mg/kg/day dose range) fail to significantly impact CEP numbers, regardless of whether they are administered for a 7-day period or longer (i.e. 28 days as shown for 6mg/kg in Fig 1b) . At the same time, we cannot exclude that metronomic LY may be toxic to CEPs; thus, for example, average CEP levels in the 6mg/kg/day LY group were slightly lower than controls (Fig 2b) . Also, at 10mg/kg/day LY a relative drop in CEPs was observed, although this effect was not specific to that cell type since we also observed a drop in white blood counts (WBC). Gemcitabine given every 3 days i.p. (Fig. 2b) is toxic to CEPs, although further studies with a larger number of mice per group are necessary to more clearly define that effect. Furthermore, we cannot exclude that the different impact that gemcitabine and LY had on CEP levels could be due to the fact that the drugs were administered differently; i.e., gemcitabine was administered i.p. every 3 days, whereas LY was administered daily by gavage. to assess the effectiveness of other metronomic chemotherapy regimens, e.g. metronomic cyclophosphamide (CTX) (14) . As a positive control treatment we employed a bolus plus low dose CTX protocol, which we previously showed to effectively inhibit tumor driven angiogenesis (25) . LY was administered at daily doses of 6mg/kg and 8mg/kg. In a separate group, gemcitabine was administered i.p. at a dose of 160mg/kg given every 3 days. We also tested combinations of LY plus the metronomic CTX protocol, in view of the fact that some drugs can elicit certain anti-tumor (or anti-angiogenic) responses only when they are combined with other treatment regimens (14) . Tumor growth was monitored by caliper measurements, and therapies were initiated when the tumors reached an average size of 250mm 3 . All treatment caused anti-tumor effects compared to the control saline treated group (Fig 3a) during the two week treatment period. The mice were then sacrificed and the tumors were removed and sectioned for microvessel density analysis. As can be seen from Fig 3b, the combination of bolus plus low-dose CTX with 8mg/kg LY showed some toxicity as indicated by weight loss. This was also observed, to a lesser extent, with the combination of bolus plus low-dose CTX and 6mg/kg LY. It should be noted that drugs such as gemcitabine may exert different levels of toxicity depending on the tumor that is implanted in the host (30) . In this regard it is noteworthy that the prodrug given at either 6mg/kg or 8mg/kg did not produce significant toxicity Figure 1) . In fact there appeared to be a slight increase in the number of vessels in these groups compared to controls. Thus in the treated group there was no major impact on the number of vessels. Therefore, metronomic LY does not seem to impact tumor angiogenesis. Quantitative fluorescence imaging of these tumors confirms these treatment effects on vascular density (Supplementary Figure 2) . Additionally, treatment with LY alone results in a decrease in large vessels, an increase in small vessels, and an increase in the Vessel Normalization Index (Supplementary Figure 2C) .
The increase in a normalization phenotype (assessed by a decreased tortuosity, increased pericyte coverage, and decreased hypoxia) suggests that metronomic LY treatment modulates vessel stability and functionality. Fig 4c) one week after treatment, and this difference increased three weeks into the treatment schedule (see Movie files 1-4, as well as Fig 4c) . Caliper measurements showed that, as expected, LY monotherapy caused the tumors to be growth inhibited compared to controls (Fig 4a) .
LM2-4luc+ tumors (compared to vehicle treated controls -see
And yet, paradoxically, the smaller, LY-treated tumors, showed equal or greater luciferase luminescence than the control tumors (Fig 4d-e) . This observation is consistent with the possibility that the increased intratumoral blood flow in the (smaller) LY-treated tumors produced a more effective delivery of the luciferin substrate. (Fig. 5a) . Furthermore, the resulting survival curve showed that LY monotherapy increased the survival of mice compared to controls (Fig 5b) . We also noted that the combination of low-dose CTX plus LY did not increase survival beyond that observed 
Discussion
Metronomic chemotherapy is emerging as a potentially important new therapeutic strategy for the treatment of a variety of solid tumors (6) (7) (8) . Effective metronomic scheduling relies on the prospective identification of a dose at which a chemotherapeutic agent can be administered in a close repetitive fashion with no prolonged breaks, with minimal toxicity. In preclinical mouse studies determination of the 'optimal metronomic dose' (OMD), i.e., the most effective biological dose at which a chemotherapeutic agent can be administered in a metronomic fashion is the equivalent to the minimum dose administered over a week long period required to elicit the maximal reduction in CEP numbers (25) . Using CEP levels as a pharmacodynamic readout, the OMD was previously determined for several different drugs such as CTX, cisplatin, and UFT among othersand in all cases the determined OMD using this approach did not cause significant host toxicity, even after very prolonged treatment (14, 23, 31) . Here we report the first example of a chemotherapeutic drug we have used that can effectively be administered in a metronomic non-toxic fashion, at doses that have little or no significant impact on CEP numbers (although a comprehensive analysis of the impact of LY on CEPs was not carried out, and is beyond the scope of this study). We also show that non-toxic metronomic doses of the prodrug of gemcitabine LY2334737 that do not suppress CEP levels can nonetheless have an impact on intratumoral blood flow and suppress tumor growth. In other words, CEP analysis failed to predict the effective metronomic dose of LY which was assessed by us to be in the range of 6-8mg/kg. (33) . Thus, since metronomic or metronomic-like chemotherapy in some cases has been shown to be effective against tumors which have acquired resistance to MTD chemotherapy of the same drug (1, 34) , it is conceivable that metronomic gemcitabine could prove effective in situations where MTD gemcitabine no longer has activity. In this regard, there is some limited clinical evidence that administering gemcitabine at doses significantly lower than the MTD -where the dose is continuously titrated using grade 1 neutropenia as a biomarker for dosing (35, 36) -may be less toxic and equally, or even more effective than MTD gemcitabine (35, 36) .
Overall our prodrug-mediated results are important for three reasons. First, they stress that caution is needed when assessing only CEP numbers for determining the OMD, even preclinically, and that additional methods may need to be developed to evaluate the most effective dose for certain drugs such as LY2334737. Second, they imply the existence of a new subclass of chemotherapeutic drugs, i.e. drugs that can be effectively administered in a metronomic fashion without impacting CEP levels (a clear distinction from most other chemotherapeutic drugs, e.g. CTX, UFT, which we have tested). Third, they provide further evidence that multiple mechanisms, including altered rate of intratumoral blood flow, likely contribute to the anti-tumor effects that result from 
metronomic chemotherapy (e.g., by enhancing the intra-tumoral delivery of anticancer agents), some of which are unrelated to the inhibition of systemic angiogenesis. Thus, in theory, the comparison between metronomic scheduling of drugs such as CTX (which impacts CEPs) and LY (which does not) should in part reveal mechanisms of action of metronomic chemotherapy that are independent of inhibition of systemic vasculogenesis or angiogenesis. Our results also raise the question of whether it may be advantageous to combine metronomic chemotherapy using two classes of drugs that differ by their mode of action. For example, in this study we tested one such combination -using metronomic CTX and LY which have different impacts on CEP levels.
An interesting and unexpected aspect of our results is the finding of increased tumor blood flow induced by the metronomic oral gemcitabine treatment, as detected by high resolution microultrasound imaging. This could conceivably lead to selectively increased levels of intra-tumoral gemcitabine despite the lower daily doses of drug administered, although this was not assessed by us. If true, this may be related to metronomic gemcitabine induced vessel normalization, a phenomenon induced by various antiangiogenic drugs (37, 38) and postulated to increase intra-tumoral delivery and distribution of co-administered chemotherapy (37, 38) . In this regard a number of impact CEP numbers. A reduction in CEP numbers was evident at higher doses (e.g 15 and 20mg/kg/day; these were significantly lower, p<0.05, compared to controls, and compared to the 8mg/kg LY treated group) but this was concomitant with excessive weight loss (shown in a), which was further confirmed by a drop in WBC (a significant difference in WBC, p<0.05, was observed between 20mg/kg LY treated mice and controls). 
